Eli Lilly has inked an exclusive research and licensing deal with Seamless Therapeutics worth up to $1.12 billion to develop programmable recombinase gene-editing therapies for ...
A new study links rare CPD gene mutations to congenital hearing loss and shows that restoring arginine–nitric oxide signaling — with supplements or sildenafil — rescues auditory...
We use cookies
We use cookies to enhance your browsing experience, serve personalized content, and analyze our traffic. By clicking "Accept", you consent to our use of cookies.
